Sensus Healthcare, Inc. is a medical device company specializing in non-invasive treatments for oncological and non-oncological skin conditions. The company develops and sells devices based on its proprietary superficial radiation therapy (SRT) technology, which provides a safe and effective alternative to surgical procedures. Its products are primarily used to treat non-melanoma skin cancers and keloids, with a focus on delivering cost-effective and minimally scarring solutions to dermatology clinics and radiation oncologists.
- SRT-100 Product Line - Offers non-invasive treatment devices for non-melanoma skin cancers and keloids, leveraging low-energy X-ray technology to provide safe and effective alternatives to surgery.
- SRT-100™ - Features a compact, mobile design with advanced safety controls and patient record management for ease of use and reliability.
- SRT-100 Vision™ - Includes enhanced features for improved treatment precision and workflow management.
- Service Revenue - Provides maintenance and support services for installed SRT units, ensuring operational reliability and customer satisfaction.
- Ancillary Products - Supplies additional products related to the SRT-100 line to support its functionality and enhance treatment outcomes.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Joseph C. Sardano ExecutiveBoard | CEO and Chairman | Board Member at Birch BioMed; Board Member at BioFlorida | Co-founder of Sensus Healthcare in 2010; over 40 years of experience in healthcare; led SRTS's growth and innovation in medical imaging and therapeutic devices. | View Report → |
Emiliano Sosa Executive | CTO | None | Joined SRTS in 2022; promoted to CTO in January 2023; extensive experience in AI, cybersecurity, and medical device development, including engineering the first GPS device in Argentina with real-time video streaming. | |
Javier Rampolla Executive | CFO | None | Joined SRTS in 2015; promoted to CFO in January 2020; played a key role in SRTS's IPO in 2016 and adoption of new U.S. GAAP guidelines. | |
Magdalena Martinez Executive | COO | None | Joined SRTS in 2013; promoted to COO in January 2023; previously served as VP of Operations and Customer Service Manager. | |
Anthony Petrelli Board | Non-Employee Director | Board Member at Ring Energy, Inc.; Financial Consultant at Momentum Independent Network; Founder of Equinox Counseling LLC | Director at SRTS since 2016; extensive experience in investment banking, corporate finance, and counseling; served on numerous regulatory and industry committees, including FINRA. | |
Megan Cornish Board | Non-Employee Director | Chief Customer Officer at Moth+Flame; Founding Board Member of Upcycled Food Association and Upcycled Food Foundation | Joined SRTS as a director in 2021; extensive experience in sustainability, food and beverage, and virtual reality; previously VP of External Affairs at FoodMaven Corporation. | |
William McCall Board | Independent Director | Managing Director at Heritage Advisory Group; Partner at Investors Capital Alliance LLC; CEO of WMW Partners LLC; Member of Pandora Mineral Resources LLC | Director at SRTS since 2015; financial advisor and portfolio manager with expertise in corporate finance and governance; holds a Chartered Wealth Advisor designation. |
- Given that your largest customer represented about 50% of placements in Q3 2024, how are you addressing the risk of revenue concentration, and what steps are you taking to diversify your customer base?
- With the Fair Deal Agreement covering up to 130 clinics of Platinum Dermatology Partners, can you provide more clarity on the expected timeline for installations and how this will impact revenue recognition, especially considering installations may extend into next year?
- Accounts receivable increased to $17 million as of September 30, 2024, compared to $11.6 million at the end of 2023, with only $8 million collected to date. What measures are you taking to manage credit risk and ensure timely collections as you scale up your business?
- You mentioned having enough inventory to cover all of 2025 and preparing orders for 2025 to be delivered in the second half of this year and into 2026. Can you elaborate on how you plan to meet potential increased demand from large agreements like with Platinum Dermatology, and whether your production capacity is sufficient?
- Gross margins improved to 59.3% in Q3 2024 from 51% in Q3 2023. Given potential pricing pressures and the shift to recurring revenue models like the Fair Deal Agreement, do you expect to maintain these margin levels moving forward?
Research analysts who have asked questions during Sensus Healthcare earnings calls.
Anthony Vendetti
Maxim Group
3 questions for SRTS
Ben Haynor
Lake Street Capital Markets
2 questions for SRTS
Benjamin Haynor
Lake Street Capital Markets
2 questions for SRTS
Eduardo Martinez-Montes
H.C. Wainwright & Co., LLC
2 questions for SRTS
Arslan Cameron
ROTH Capital Partners
1 question for SRTS
Jade Montgomery
H.C. Wainwright
1 question for SRTS
Jason Wittes
Roth Capital Partners, LLC
1 question for SRTS
Jeremy Pearlman
Analyst
1 question for SRTS
Yi Chen
H.C. Wainwright & Co.
1 question for SRTS
Recent press releases and 8-K filings for SRTS.
- Bragar Eagel & Squire, P.C. is investigating Sensus Healthcare, Inc. (SRTS) on behalf of its stockholders for potential violations of federal securities laws and/or unlawful business practices.
- This investigation follows Sensus's Q2 2025 financial results, reported on August 7, 2025, where the company reported a GAAP earnings-per-share of -$0.06, missing estimates by $0.09.
- Sensus's revenue for Q2 2025 was $7.3M, representing a 20.7% year-over-year decline and missing estimates by $2M. The decrease was primarily attributed to a lower number of units sold to a large customer.
- Following this news, Sensus's stock price fell $1.89 per share, or 35.32%, to close at $3.46 per share on August 8, 2025.
- The Portnoy Law Firm has initiated an investigation into Sensus Healthcare, Inc. (SRTS) for possible securities fraud and may file a class action lawsuit on behalf of investors.
- This investigation follows Sensus's Q2 2025 financial results, reported on August 7, 2025, which showed a GAAP earnings-per-share loss of $0.06 (missing analyst estimates by $0.09) and revenue of $7.3 million (a decline of 20.7% year-over-year and below estimates by $2 million).
- The company attributed the revenue decline primarily to a reduction in units sold to a large customer.
- Following these results, Sensus's stock price declined $1.89 per share, or approximately 35.3%, to close at $3.46 per share on August 8, 2025.
- The Schall Law Firm is investigating Sensus Healthcare, Inc. (SRTS) for potential violations of securities laws, focusing on whether the Company issued false or misleading statements or failed to disclose pertinent information to investors.
- This investigation follows Sensus's Q2 2025 financial results, reported on August 7, 2025, which included a significant miss on earnings per share and a 20.7% year-over-year revenue decrease.
- The Company attributed the revenue decline to lower sales to a large customer.
- Following the news, Sensus shares fell by more than 35.2% the next day.
- Sensus Healthcare, Inc. (Nasdaq: SRTS) has received Medical Device Single Audit Program (MDSAP) certification for its entire portfolio of superficial radiation therapy (SRT) systems, including the SRT-100®, SRT-100+™, and SRT-100 Vision™.
- This certification is expected to streamline international regulatory efforts and enable faster commercial expansion into key global markets by allowing a single audit to satisfy Quality Management System (QMS) requirements for the U.S. FDA, Health Canada, Brazil’s ANVISA, Japan’s PMDA, and Australia’s TGA.
- The company anticipates that MDSAP certification will reduce approval timelines and associated costs in recognizing jurisdictions, enhancing the ability of Sensus’ international sales and distribution teams to engage hospital systems and specialty clinics.
- Sensus Healthcare’s TransDermal Infusion (TDI) product is also expected to be granted MDSAP certification upon receipt of FDA clearance, which would enhance its commercial prospects outside the U.S..
- Q1 2025 results: Revenue of $8.3 million paired with a net loss of $2.6 million, reflecting a mixed financial performance
- Shipped 21 SRT systems – including a significant order from a large customer – which expanded the installed base to over 880 systems with a target to exceed 900 in Q2
- Reported a 65% increase in FDA treatment volume over the previous quarter, underscoring robust growth in patient treatments
- Strategic investments in sales, marketing, and R&D (including a resubmitted 510(k) application for the TDI and expansion of the Fair Deal Agreement program) are aimed at driving recurring revenue and long-term growth
- Management expects a return to profitability within the next three quarters and for the full year, despite current challenges